Abstraction Health

NMN (Nicotinamide Mononucleotide) — Stack & Timing

Educational timing and stacking information based on how NMN (Nicotinamide Mononucleotide) has been studied. Not a prescription. Not medical advice.

This is educational information only. Consult a healthcare provider before starting any supplement.

Stack & Timing Guidance

Educational summary based on how NMN (Nicotinamide Mononucleotide) has been studied and commonly used.

🟡Moderate Evidence

Commonly studied timing

Morning

Morning dosing is consistently preferred by experts such as Huberman and Patrick based on the rationale that NAD+ precursors may support circadian-aligned energy metabolism; no robust RCT data currently specifies an optimal time of day, so this reflects expert consensus rather than confirmed trial evidence.

Dose ranges used in studies

2501200 mg

Clinical trials have investigated doses ranging from 250 mg to 1200 mg per day, with several RCTs using 300–600 mg as common test doses; optimal dosing has not been established and varies by study population, formulation, and outcome measured.

↑ These are ranges from research studies, not personal dosing recommendations. Discuss with a clinician.

Commonly paired with

Resveratrol

Resveratrol is a sirtuin activator, and sirtuins require NAD+ as a cofactor; the combination is theorized to amplify NAD+-dependent sirtuin signaling

TMG (Trimethylglycine / Betaine)

NMN metabolism may consume methyl groups; TMG is taken as a methyl donor to theoretically offset any methylation burden

Vitamin D3

Both are commonly included in longevity-oriented supplement protocols; Vitamin D3 has independent evidence for metabolic and immune health that may complement NAD+ pathway support

Quercetin

Quercetin is a senolytic with proposed anti-inflammatory and NAD+-pathway-adjacent effects, and is sometimes stacked with NMN in longevity protocols

Safety & interactions

Available RCT data suggest NMN is generally well tolerated in healthy adults at doses up to at least 1200 mg/day over the periods studied, with no serious adverse events reported in safety-focused trials; long-term safety data in humans remain limited, and most studies are of short to moderate duration.

Known interactions
  • Theoretically may interact with chemotherapy agents due to NAD+ pathway involvement in DNA repair — caution warranted in oncology contexts
  • May have additive effects with other NAD+ precursors (e.g., NR, niacin, niacinamide) potentially affecting methylation balance
Contraindications

Individuals with active cancer or a history of hormone-sensitive cancers should exercise caution and consult a physician, as NAD+ elevation could theoretically support tumor cell metabolism; pregnant or breastfeeding individuals should avoid use due to absence of safety data; those on medications affecting NAD+ metabolism or DNA repair pathways should seek medical guidance before use.

Evidence basis: Guidance is based on a body of moderate-quality RCTs demonstrating NAD+ blood level increases and select functional outcomes (insulin sensitivity, walking speed, aerobic capacity), supplemented by mechanistic review literature and consistent expert practitioner consensus on dosing and timing.